Dr. Kuerer Discusses Sentinel Node Clipping

Henry M. Kuerer, MD, PhD, FACS
Published Online: Friday, March 28, 2014
Henry M. Kuerer, MD, PhD, FACS, professor of surgery, Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, discusses sentinel node clipping for post-chemotherapy identification.

There has been a paradigm shift in the local management of patients with node-positive breast cancer. It is known that chemotherapy and biologic agents can completely eradicate disease in approximately 3-6 months in a significant amount of patients.

Results from the ACOSOG Z1071 (Alliance) clinical trial led by Judy C. Boughey, MD, showed that the current sentinel node procedure has a fairly high false negative rate. There remains a need to be more accurate and do fewer surgeries.

At The University of Texas MD Anderson Cancer Center, Kuerer says, a trial was completed in which physicians biopsied a patient’s lymph nodes, put a clip, and used an I-125 seed at the end to ensure that the node was removed and tested.

Other trials are ongoing that will hopefully minimize surgery, even for node positive patients.

Online CME Activities
Free CME from PER
Community Practice Connections: 13th Annual International Congress on the Future of Breast Cancer®
Highlights From the 13th Annual International Congress on the Future of Breast Cancer®
Pancreatic Cancer: Novel and Emerging Approaches to Early Detection and Treatment
Oncology Best Practice: Challenges in Treating Chronic Lymphocytic Leukemia – The Older Patient and Comorbid Conditions
More Reading
Publications
$auto_registration$